The Longevity Registry

§ — Substance profile

A

Semaglutide

Ozempic · Wegovy · Rybelsus · GLP-1 receptor agonist

01 — Regulatory status

Regulatory status · United States · as of October 2026

FDA-approved for type 2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk reduction in adults with obesity. FDA declared the shortage resolved in February 2025; the grace periods for compounding pharmacies ended in April (503A) and May (503B) 2025. Compounded copies are no longer permitted on shortage grounds.

Source: FDA 503A Bulks List · PCAC meeting records · verified October 2026

A
Approved drug with randomized controlled trials for the approved indication
B
Human clinical data exists, but no approval for the researched use
C
Animal or in-vitro data only, no controlled human trials
D
No published clinical data; use rests on anecdote

Reviewed October 2026 · Sources: FDA, EMA

02 — Researched for

What is being studied.

Type 2 diabetes, obesity, cardiovascular outcomes, NASH, kidney outcomes, alcohol use, Alzheimer's disease.

03 — What the evidence shows

The published record.

Large randomized trials: roughly 15% mean weight loss at 68 weeks and a 20% relative reduction in major cardiovascular events in adults with obesity and established cardiovascular disease.

04 — What is claimed but not shown

Claimed, not demonstrated.

Benefit in normal-weight adults; preservation of lean mass without resistance training; safe use of unregulated compounded product.

05 — Known risks

Documented risks.

Gastrointestinal effects, gallbladder events, pancreatitis signal, lean mass loss; weight regain after discontinuation; counterfeit and mis-dosed grey-market product.

06 — Researched for these goals

Where Semaglutide appears.

Related substances

07 — Questions for your physician

Six questions worth printing.

  1. 01What is your primary board certification, and in what year did you obtain it?
  2. 02Is this peptide approved for what you are prescribing it for — and if not, what is the legal basis on which you are supplying it?
  3. 03Which human trials support this use, and what were their size and duration?
  4. 04Where does the product come from, and can you show me a certificate of analysis for this batch?
  5. 05What outcome will we measure, when, and what happens if it does not improve?
  6. 06What is the total cost for the first three months, in writing?

Practices near you that offer peptide therapy

Every practice in the registry that lists peptide therapy, sorted by distance and nothing else. You contact the practice directly.

Listed for transparency, not as an endorsement of any practice, substance or protocol. Most peptides are not FDA-approved for the uses they are offered for.

Reviewed October 2026 · Sources: FDA, EMA

This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.